This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Allopurinol in Acute Gout

This study has been withdrawn prior to enrollment.
(because of a lack of funding)
Sponsor:
Information provided by (Responsible Party):
Artur de Brum-Fernandes, Université de Sherbrooke
ClinicalTrials.gov Identifier:
NCT01775098
First received: January 21, 2013
Last updated: May 10, 2017
Last verified: May 2017
  Purpose
The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises

Condition Intervention
Gout Drug: allopurinol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
Official Title: Allopurinol in Acute Gout The Title Will Not be Change as the Study as Been Closed.

Resource links provided by NLM:


Further study details as provided by Artur de Brum-Fernandes, Université de Sherbrooke:

Primary Outcome Measures:
  • Duration of the gout crises [ Time Frame: First 7 days after visit ]
    Presence of inflammatory signs


Enrollment: 0
Study Completion Date: February 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allopurinol
treatment with allopurinol
Drug: allopurinol
No arms will not be change as the study as been closed.
Placebo Comparator: placebo
placebo comparator
Drug: allopurinol
No arms will not be change as the study as been closed.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis

Exclusion Criteria:

Les than 18 years-old Unable to consent Contra-indication to allopurinol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Artur de Brum-Fernandes, Doctor, Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT01775098     History of Changes
Other Study ID Numbers: Allopurinol in acute gout
Study First Received: January 21, 2013
Last Updated: May 10, 2017

Keywords provided by Artur de Brum-Fernandes, Université de Sherbrooke:
Gout
uric acid
allopurinol

Additional relevant MeSH terms:
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Allopurinol
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 26, 2017